These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17584041)

  • 21. Comparison Between Metabolic Syndrome and the Framingham Risk Score as Predictors of Cardiovascular Diseases Among Kazakhs in Xinjiang.
    Yang W; Ma R; Zhang X; Guo H; He J; Mao L; Mu L; Hu Y; Yan Y; Liu J; Ma J; Li S; Ding Y; Zhang M; Zhang J; Guo S
    Sci Rep; 2018 Nov; 8(1):16474. PubMed ID: 30405180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.
    Birnbaum Y; Ye Y; Bajaj M
    J Diabetes Complications; 2017 Feb; 31(2):291-294. PubMed ID: 27780670
    [No Abstract]   [Full Text] [Related]  

  • 23. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome.
    Yamaoka-Tojo M; Tojo T; Izumi T
    Curr Vasc Pharmacol; 2008 Oct; 6(4):271-81. PubMed ID: 18855715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Metabolic syndrome and the role of the polypill in the prevention of its complications].
    Rosolová H
    Vnitr Lek; 2017; 63(10):712-716. PubMed ID: 29127755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rise and fall of the metabolic syndrome.
    Borch-Johnsen K; Wareham N
    Diabetologia; 2010 Apr; 53(4):597-9. PubMed ID: 20084362
    [No Abstract]   [Full Text] [Related]  

  • 26. Metabolic disorders increase the risk to incident cardiovascular disease in middle-aged and elderly Chinese.
    Zhang ML; Hou XH; Zhu YX; Lu JX; Peng LP; Gu HL; Jia WP
    Biomed Environ Sci; 2012 Feb; 25(1):38-45. PubMed ID: 22424625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cardiometabolic syndrome and cardiovascular disease.
    Ash-Bernal R; Peterson LR
    J Cardiometab Syndr; 2006; 1(1):25-8. PubMed ID: 17675903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The metabolic syndrome as a prohypertensive state.
    Mulé G; Cerasola G
    Am J Hypertens; 2008 Jan; 21(1):8. PubMed ID: 18268791
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts.
    Ünlü M; Balta Ş; Arslan Z; Öztürk C; Çelik T; Iyisoy A
    Cardiology; 2015; 130(1):52-3. PubMed ID: 25531655
    [No Abstract]   [Full Text] [Related]  

  • 30. [New targets in patients with cardiometabolic risk].
    Ruilope LM; Carmena R
    Med Clin (Barc); 2007 Oct; 129(15):576-7. PubMed ID: 17988615
    [No Abstract]   [Full Text] [Related]  

  • 31. The metabolic syndrome: a call to action.
    Gotto AM; Blackburn GL; Dailey GE; Garber AJ; Grundy SM; Sobel BE; Weir MR
    Coron Artery Dis; 2006 Feb; 17(1):77-80. PubMed ID: 16374146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of blood pressure and other components of the metabolic syndrome on the development of cardiovascular disease.
    Kang G; Guo L; Guo Z; Hu X; Wu M; Zhou Z; Zhou H; Liu S; Chen F
    Circ J; 2010 Mar; 74(3):456-61. PubMed ID: 20057161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
    Després JP
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic syndrome.
    Dominiczak MH
    Curr Opin Lipidol; 2003 Jun; 14(3):329-32. PubMed ID: 12840663
    [No Abstract]   [Full Text] [Related]  

  • 35. Response to the paper by Ünlü et al. entitled 'The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts'.
    Li J; Song SJ
    Cardiology; 2015; 130(1):54. PubMed ID: 25531774
    [No Abstract]   [Full Text] [Related]  

  • 36. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness.
    Kreyenbuhl J; Dickerson FB; Medoff DR; Brown CH; Goldberg RW; Fang L; Wohlheiter K; Mittal LP; Dixon LB
    J Nerv Ment Dis; 2006 Jun; 194(6):404-10. PubMed ID: 16772856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Metabolic syndrome and cardiovascular diseases in HIV patients].
    Seybold U
    MMW Fortschr Med; 2012 May; 154 Suppl 1():30-1. PubMed ID: 22916595
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study.
    Kim NH; Han KH; Choi J; Lee J; Kim SG
    BMJ; 2019 Sep; 366():l5125. PubMed ID: 31562117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevalence of cardio metabolic risk factors and related socio-demographic factors in adults aged 18-59 years in 15 provinces of China].
    Wang ZH; Zhang B; Wang HJ; Wang LS; Ding GG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Jul; 39(7):904-908. PubMed ID: 30060302
    [No Abstract]   [Full Text] [Related]  

  • 40. Insulin therapy for reducing cardiovascular risk in patients with type 2 diabetes.
    Bohannon N
    Clin Cornerstone; 2003; Suppl 4():S21-7. PubMed ID: 14986905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.